Fig. 1

a Distribution of HPV genotypes in 95 sub-study-1 18-year-old girls in 2013, five years after having been offered Gardasil®.

Genotypes were determined with the Anyplex™ II HPV28 kit and restricted to those shared with the PGMY-CHUV assay. The seven most prevalent genotypes by decreasing occurrences among vaccinees and non vaccinees were HPV42, 51, 53, 66, 39, 52 and 59. Members of the Gardasil® vaccine ranked 14th (HPV16), 20th (HPV6) and 23rd (HPV11 and 18). Vaccine did not affect the repartition of either genotypes among the non-vaccinated and vaccinated subjects (p > 0.05, not shown) although differences would be difficult to identify due to the low number of cases. The relatively high prevalence of HPV42 may in part be due to a higher sensitivity of Anyplex™ II HPV28 compared with PGMY-CHUV for this genotype. HPV genotyping with both assays is otherwise highly comparable [15]. b Distribution of HPV genotypes in 2272 HPV-positive sub-study-2 outpatients stratified in three age-groups referred to HPV testing from 1999 till 2007. Genotypes were determined with the PGMY-CHUV assay and restricted to those shared with the Anyplex™ II HPV28 kit. The seven most prevalent genotypes by decreasing occurrences among the youngest women (<26) were HPV16, 53, 51, 66, 58, 6, and 52. Members of the Gardasil® vaccine ranked first (HPV16), sixth (HPV6), 10th (HPV18) and 21st (HPV11)